Advancing the science of medicines regulation: The role of the 21st-century medicines regulator

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 4, 2012, Pages 486-493

  Lumpkin, M M ^a   Eichler, H G ^b   Breckenridge, A ^c   Hamburg, M A ^a   Lonngren T ^b,d   Woods, K ^b,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^d Private Consultancy in Health Technology Assessment and Pharmaceutical Develoment   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERANCE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; LEGAL ASPECT; MEDICINE REGULATION; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SCIENCE;

DELIVERY OF HEALTH CARE; DRUG AND NARCOTIC CONTROL; HUMANS; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84866623189     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.146     Document Type: Review

References (27)

1. US Food and Drug Administration. Advancing Regulatory Science for Public Health http://www.fda.gov/downloads/ScienceResearch/Specialtopics/Regulatory Science/UcM228444.pdf (2010).
2. US Food and Drug Administration. FDA, EMA announce pilot for parallel assessment of Quality by Design applications http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm247332.htm (16 March 2011).
3. US Food and Drug Administration. EMA-FDA Pilot Program for Parallel Assessment of Quality by Design Applications. EMA/17234/2011 http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/UcM248526.pdf
4. http://www. ema.europa.eu/ema/index.jsp?curl=pages/includes/document/ document-detail.jsp?webcontentId=Wc500103621 & mid=Wc0b01ac058009a3dc (16 March 2011).
5. US Food and Drug Administration. Guidance for Industry: Pharmacogenomic Data Submissions http://www.fda.gov/downloads/Drugs/ GuidancecomplianceRegulatoryInformation/Guidances/UcM079849.pdf (March 2005)
6. US Food and Drug Administration. Guidance for Industry and FDA Staf: Pharmacogenetic tests and Genetic tests for Heritable Markers http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm071075.pdf (19 June 2007)
7. US Food and Drug Administration and European Medicines Agency. Processing Joint FDA EMEA Voluntary Genomic Data Submissions within the Framework of the confdentiality Arrangement http://www.fda.gov/downloads/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/UcM085378.pdf (19 May 2006).
8. US Food and Drug Administration. Biomarker Qualifcation Program http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DrugDevelopmenttoolsQualifcationProgram/ucm284076.htm (5 March 2012).
9. US Food and Drug Administration. Letter from Janet Woodcock and John Jenkins to Frank Dieterle et al. http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DrugDevelopmenttoolsQualifcationProgram/UcM285031. pdf (14 April 2008).
10. Critical Path Institute. Predictive Safety testing consortium (PStc). http://www.c-path.org/pstc.cfm.
11. US Food and Drug Administration. Predictive Safety testing consortium (PStc) http://www.fda.gov/AboutFDA/Partnershipscollaborations/ PublicPrivatePartnershipProgram/ucm231132.htm (11 November 2010).
12. Sacks, L.V. & Behrman, R.E. Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective. Tuberculosis 99 (suppl. 1), S93-100 (2008).
13. Critical Path Institute. critical Path to tB Drug Regimens (cPtR) http://www.c-path.org/cPtR.cfm.
14. Goodman, J. Statement before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, committee on Appropriations, US Senate http://www.fda.gov/NewsEvents/testimony/ucm216991.htm (23 June 2010).
15. US Food and Drug Administration. Guidance for Industry: Adaptive Design clinical trials for Drugs and Biologics. http://www.fda.gov/downloads/Drugs/ GuidancecomplianceRegulatoryInformation/Guidances/UcM201790. pdf (February 2010)
16. European Medicines Agency. EMA/EFPIA 2nd Workshop: Adaptive Design in confrmatory trials http://www.ema.europa.eu/docs/en-GB/document- library/Minutes/2010/04/Wc500089206.pdf.
17. Eichler, H.G. et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91, 426-437 (2012).
18. Ethical and Scientifc Issues in Studying the Safety of Approved Drugs (Washington, Dc, National Academies Press, 2012).
19. Alvarez, Y., Hidalgo, A., Maignen, F. & Slattery, J. Validation of statistical signal detection procedures in EudraVigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf. 33, 475-487 (2010).
20. Raine, J., Wise, L., Blackburn, S., Eichler, H.G. & Breckenridge, A. European perspective on risk management and drug safety. Clin. Pharmacol. Ther. 89, 650-654 (2011).
21. US Food and Drug Administration. FDA's Sentinel Initiative. transforming How We Monitor the Safety of FDA-Regulated Products http://www.fda.gov/safety/ FDAsSentinelInitiative/ucm2007250.htm (May 2008).
22. Smeraldi, C. ENcePP: Where Are We and Where are We Going? European Medicines Agency http://www.ema.europa.eu/docs/en-GB/document-library/ Presentation/2011/11/Wc500117945.pdf (16 June 2011).
23. European Medicines Agency. EMEA-coordinated PROtEct Project has been Accepted for Funding by the Innovative Medicines Initiative Joint Undertaking http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2009/11/ Wc500011238.pdf (29 April 2009)
24. US Food and Drug Administration. Draft Guidance for Industry: Animal Models-Essential Elements to Address Efcacy Under the Animal Rule. http://www.fda.gov/downloads/Drugs/GuidancecomplianceRegulatoryInformation/ Guidances/ucm078923.pdf (January 2009).
25. Goldman, M. the innovative medicines initiative: a European response to the innovation challenge. Clin. Pharmacol. Ther. 91, 418-425 (2012).
26. Woodcock, J. & Woosley, R. the FDA critical path initiative and its infuence on new drug development. Annu. Rev. Med. 59, 1-12 (2008).
27. Food and Drug Administration Safety and Innovation Act (2012). Section 1124.